Diabetic Women More Likelier to Suffer from Heart Attack Compared To Diabetic Men

Diabetic women are around 40 percent more likely to suffer from heart attack than diabetic men, shows a new study of approximately 11 million patients.

In the study, the authors undertook a systematic review and meta-analysis to estimate the relative risk for acute coronary syndrome associated with diabetes in men and women. A total of 9 case-control and 10 cohort studies were included, with data for 10,856,279 individuals and at least 106703 fatal and non-fatal acute coronary syndrome events.

Drug Used for Treating Gallstone-Related Spasms May Help Prevent Type-1 Diabetes
A substance called hyaluronan, in the pancreas during the pre-symptomatic stage of Type-1 diabetes is essential to the development of the disease.

The pooled maximum-adjusted relative risk of acute coronary syndrome associated with diabetes was 2.46 in women and 1.68 in men. In patients with diabetes, women therefore had a significantly greater risk of acute coronary syndrome, with a 38 percent increased risk for women.

According to author Xue Dong of the ZhongDa Hospital of Southeast University, women with diabetes had a roughly 40 percent greater excess risk of acute coronary syndrome, compared with men with diabetes. They said that people should take all necessary steps to diagnose diabetes early, and control risk factors comprehensively to guarantee the most suitable treatments and best possible outcomes in female patients.

Source-ANI

Blood Sugar Control Help Prevent Dementia In Type 2 Diabetes Patients
The authors conducted extensive clinical data to explore the association between HbA1c and the risk of hospitalization for dementia among persons with type 2 diabetes.

Areas With Higher Prevalence Of Diabetes Have Fewer Healthy Food Options
About 28% of neighborhoods in the western Australia, had 3:1 ratio of takeaway shops to greengrocers and super markets as well as higher rate of Type-2 Diabetes.

Sanofi�s New Diabetes Drug LixiLan Shows Promising Results in Phase III Trial
Sanofi, a global healthcare leader, has announced that a second late-stage Phase III study of its LixiLan diabetes drug had met its main target.